ArticleJournal of translational medicine2025
Machine learning-enhanced discovery of a basement membrane-related gene signature in glioblastoma via single-cell and Spatial transcriptomics.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative multi-omics analysis and machine learning identify M2 macrophage-induced ferroptosis resistance in glioblastoma.Functional & integrative genomics · 2026Article
- Defining neurovascular ecosystem states with single-cell multi-omics and machine learning: insights into cerebrovascular remodeling in the tumor context.Frontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe complex invasiveness and heterogeneity of glioblastoma multiforme (GBM) hinder the complete eradication of the tumor. The invasion of the basement membrane (BM) occurs before the spread to the meninges and the metastasis of glioma cells, increasing the recurrence rate of the disease, leading to poor patient prognosis.
methodsIn this study, four cohorts of GBM patients were aggregated to confirm the BM candidate genes through binary classification machine learning (ML). We delineated their features and developed a novel BM related genes (BMRGs) risk model through ML combinations, and compared it with previous models. Concurrently, the immune attributes of high and low-risk groups were analyzed using the immune infiltration algorithm encompassing CIBERSORT, xCell, and ssGSEA. Novel immunotherapeutic and chemotherapeutic strategies were proposed based on the assessment of immune treatment evaluation tools, TIDE and IRnet, and drug sensitivity analysis. Lastly, single-cell and spatial transcriptomics were utilized to unearth the properties of tumor cells with high BMRGs expression which were then verified via independent cohorts incorporating 42 samples from 17 patients.
resultsIn accordance with ML combinations, four BMRGs provided the foundation for the predictive model, serving to categorize patients into groups of high and low risk. It was observed that increased risk scores correlated with diminished overall survival rates. Immune infiltration analysis revealed that high-risk group was characterized by a heightened infiltration of M2-like macrophages and a decrease in CD8 T cells. Concurrently, it was noted that high-risk group had reduced immunotherapy benefit scores. A drug sensitivity analysis revealed that high-risk group exhibited greater sensitivity towards five drugs. Furthermore, single-cell RNA sequencing (scRNA-seq) analyses discerned tumor cells with a high BMRGs score demonstrated more effective intercellular communication. The concluding observations revealed that BMRGs have enhanced expression and significant co-localization within GBM samples.
conclusionThis study elucidates a direct molecular correlation between GBM and BM, establishes a BMRGs signature risk model, and explores their interconnectivity. The findings offer pivotal insights into the clinical outcomes, therapeutic responses, and potential treatment strategies for GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.